Physician profile
Peter Dsa
NPI 1730188129
$5,982.11
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $1,645 · 2021: $1,516 · 2022: $1,269.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,681.88 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,316.17 | 2019-2022 | |
| Gilead Sciences, INC. | $548.18 | 2019-2022 | |
| Janssen Biotech, INC. | $519.95 | 2019-2022 | |
| Pfizer INC. | $513.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $349.28 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $220.55 | 2019 | |
| Redhill Biopharma INC. | $143.32 | 2020-2021 | |
| Qol Medical, LLC | $109.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $90.54 | 2020 | |
| Braintree Laboratories, INC. | $90.52 | 2019-2022 | |
| Ucb, INC. | $84.84 | 2019 | |
| Celgene Corporation | $68.16 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $65.83 | 2020-2022 | |
| Allergan, INC. | $57.71 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $43.93 | 2020 | |
| Ardelyx, INC. | $43.14 | 2022 | |
| Shionogi INC | $20.07 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.